N-terminal fragment of pro-brain natriuretic peptide (NT-proBNP) for predicting silent myocardial ischaemia in type 2 diabetes mellitus independent of microalbuminuria

Diabetes/Metabolism Research and Reviews

Volumn 26, Issue 7, 2010, Pages 534-539

  Hamano, Kumiko ^a   Abe, Mariko ^a   Komi, Rieko ^a   Kobayashi, Shuzo ^a,b  

^a Yokohama General Hospital   (Japan)

^b SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Microalbuminuria; NT proBNP; Subclinical myocardial ischaemia

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; HEMOGLOBIN A1C; LIPID;

ADULT; ALBUMINURIA; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MALE; MICROALBUMINURIA; MULTIDETECTOR COMPUTED TOMOGRAPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SILENT MYOCARDIAL ISCHEMIA; SMOKING;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENOSIS; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 78651484464     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1113     Document Type: Article

References (20)

1. Rosamond WD, Chambless LE, Folsom AR, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Engl J Med 1998; 339: 861-867.
2. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: who to screen. Diabetes Care 1999; 22: 1396-1400.
3. Wackers FJ, Young LH, Inzucchi SE, et al. Detection of Ischemia in Asymptomatic Diabetics Investigators: detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care 2004; 27: 1954-1961.
4. Fornengo P, Bosio A, Epifani G, Pallisco O, Mancuso A, Pascale C. Prevalence of silent myocardial ischaemia in newonset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. Diabet Med 2006; 23: 775-779.
5. Bacci S, Villella M, Villella A, et al. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: applicability and accuracy of the exercise stress test. Eur J Endocrinol 2002; 147: 649-654.
6. Djaberi R, Beishuizen ED, Pereira AM, et al. Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia 2008; 51: 1581-1593.
7. Bibbins-Domingo K, Gupta R, Na B, et al. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. J Am Med Assoc 2007; 297: 169-176.
8. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction: a community-based study. Circulation 2004; 109: 3176-3181.
9. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Aminoterminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353.
10. Tarnow L, Gall MA, Hansen BV, Hovind P, Parving HH. Plasma N-terminal pro-B-type natriuretic peptide and mortality in type 2 diabetes. Diabetologia 2006; 49: 2256-2262.
11. Andersen NH, Poulsen SH, Knudsen ST, Heickendorff L, Mogensen CE. NT-proBNP in normoalbuminuric patients with Type 2 diabetes mellitus. Diabet Med 2005; 22: 188-195.
12. Kuzuya T, Nakagawa S, Satoh J, et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002; 55: 65-85.
13. Mann JF, Yi QL, Gerstein HC. Albuminuria as a predictor of cardiovascular and renal outcomes in people with known atherosclerotic cardiovascular disease. Kidney Int Suppl 2004; 92: S59-63.
14. Ordonez-Llanos J, Collinson PO, Christenson RH. Aminoterminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008; 4(101): 9-15.
15. Casco VH, Veinot JP, Kuroski de Bold ML, Masters RG, Stevenson MM, de Bold AJ. Natriuretic peptide system gene expression in human coronary arteries. J Histochem Cytochem 2002; 50: 799-809.
16. Somaratne JB, Whalley GA, Bagg W, Doughty RN. Early detection and significance of structural cardiovascular abnormalities in patients with Type 2 diabetes mellitus. Expert Rev Cardiovasc Ther 2008; 6: 109-125.
17. Huelsmann M, Neuhold S, Strunk G, et al. NT-proBNP has a high negative predictive value to rule-out short-term cardiovascular events in patients with diabetes mellitus. Eur Heart J 2008; 29: 2259-2264.
18. Vergès B, Zeller M, Beer JC, Cotton Y. RICO Survey Working Group. Plasma N-terminal Pro-Brain Natriuretic Peptide (NtproBNP) level and prognosis after myocardial infarction in diabetes. Diabetes Metab 2008; 34(Suppl. 1): S10-S15.
19. Cosson E, Nguyen MT, Pham I, Pontet M, Nitenberg A, Valensi P. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. Diabet Med 2009; 26: 872-879.
20. Schuijf JD, Bax JJ, Jukema JW, et al. Noninvasive angiography and assessment of left ventricular function using multislice computed tomography in patients with type 2 diabetes. Diabetes Care 2004; 27: 2905-2910.